T he confirmation of prior concerns of increased cardiovascular risk from rofecoxib in a randomized placebocontrolled trial led to the voluntary withdrawal of that cyclooxygenase (COX-2) inhibitor and intense scrutiny of other agents in the class. [1] [2] [3] [4] We reported cardiovascular risk related to another COX-2 inhibitor, celecoxib, in a randomized placebo-controlled trial, Adenoma Prevention with Celecoxib (APC). That report also mentioned a preliminary analysis of a similar randomized placebo-controlled trial, Prevention of Spontaneous Adenomatous Polyps (PreSAP), which did not show a statistically significant increase in Clinical Perspective p 1035 cardiovascular risk in patients receiving celecoxib 400 mg once daily but could not exclude a hazard ratio similar to that observed in APC. 5 These findings resulted in the suspension of study drug administration in both trials without interruption of patient follow-up for the primary study outcome, prevention of adenomas. 6 The possibility of discrepancy between the effect of celecoxib on cardiovascular outcomes in APC and PreSAP raises an important question as to whether the different dose regimens have different biological effects on the cardiovascular system. While the studies were proceeding, the National Cancer Institute and the Data Safety Monitoring boards of the studies established an independent cardiovascular safety committee to assess the effect of celecoxib on cardiovascular events. Before unblinding the data from either trial, the committee adjudicated serious cardiovascular events and categorized them into various composite end points. The use of uniform definitions and procedures provided an opportunity to synthesize data from both trials to obtain a combined estimate of risk. Both trials collected data on blood pressure at baseline and 1 and 3 years, allowing further exploration from randomized trial data of the cardiovascular effects of the different dosing regimens.
Methods Patients
The APC and PreSAP trials both compared the efficacy and safety of celecoxib with placebo in reducing colorectal adenomas among patients with a high risk of colorectal adenoma recurrence over a 3-year surveillance period after endoscopic polypectomy. Patients in both trials underwent colonoscopy at 1 and 3 years after study entry. The APC trial, which enrolled patients in North America, the United Kingdom, and Australia, studied celecoxib at doses of 200 mg twice daily and 400 mg twice daily; the PreSAP trial, which enrolled patients from 32 countries, including the United States, on 6 continents, studied 400 mg celecoxib once daily. Patients were not excluded for preexisting cardiovascular disorders. Descriptions of each study design and results are presented elsewhere. 7, 8 Institutional review boards approved the study protocols, and all patients provided written informed consent. Patients were randomly assigned to treatment in a 1:1:1 ratio for the APC study and a 3:2 ratio of celecoxib to placebo in the PreSAP study. Each study stratified randomization by use or nonuse of low-dose aspirin at baseline. Randomization also was stratified by country in PreSAP and by center in APC. Both studies assessed baseline cardiovascular disease status and risk factors for cardiovascular disease.
Review of Cardiovascular Safety
The Cardiovascular Safety Committee, formed at the request of the Data Safety Monitoring boards of both studies, was funded by the National Cancer Institute. The committee developed uniform endpoint definitions as guidelines for adjudication and a statistical analysis plan, as previously described. 9 All serious adverse events were collected while the studies were ongoing, and the study sites were required to submit serious adverse events in a timely fashion, which were then investigated by study monitors. Each serious adverse event was reviewed by the Cardiovascular Safety Committee for consideration as a possible cardiovascular event. For all serious adverse events identified as cardiovascular, source documentation was reviewed by the Cardiovascular Safety Committee.
A hierarchical analysis was performed to explore the effect of celecoxib on various composite cardiovascular end points. Before simultaneous unblinding of the 2 trials, the Cardiovascular Safety Committee selected the composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure as the primary cardiovascular safety end point. Cox regression analysis, stratified by use or nonuse of low-dose aspirin, was used to estimate hazard ratios for each listed hierarchical outcome. The studies were both designed to have 37 months of follow-up for serious adverse events, which was 1 month longer than the planned period of study drug. For the purpose of the analyses of the adjudicated cardiovascular end points, patients were censored at the time of death, 37 months after randomization, or January 31, 2005, whichever came first. The choice of January 31, 2005, for the censoring of patients who had not completed the study arose from the decision to stop study medication on December 17, 2004 , by the leadership of the 2 studies. Because not all patients would have stopped their medication on exactly December 17, January 31, 2005, represented a convenient cutoff date consistent with assigning each participant Ϸ1 month of follow-up. After the trials announced cessation of study medication, the study teams asked the site investigators to query each patient whose follow-up had not been regular regarding serious cardiovascular events. Under the censoring scheme described, both studies had follow-up information on Ͼ90% of the patient-years at risk. Incidence rates were calculated for individual and composite cardiovascular events by dividing the number of patients with events by the person-time at risk.
Blood Pressure
In both studies, seated blood pressure was measured in all randomized patients at baseline. Follow-up seated blood pressure measurements were made at 1 and 3 years after randomization. Mean blood pressures and changes from baseline to 1 and 3 years were analyzed post hoc using all reported values. ANOVA was used to calculate differences between the changes for the celecoxib groups and their respective placebo groups, along with their associated 95% confidence intervals (CIs). The percentage of patients in each treatment group with rises in systolic blood pressure Ͼ10 and Ͼ15 mm Hg from baseline was calculated, and 2 tests were used to calculate the statistical significance of the differences.
Combined Analysis
A combined analysis not specified in either protocol was performed using the raw data from each of the 2 trials, stratifying by trial. All analyses compared each dose with its own placebo, and all statistical models included a term for baseline aspirin use. The first Cox model compared the 2 doses in the APC study. If the effect of these doses did not differ significantly, a Cox model combining both studies tested whether the effect of celecoxib differed by study. Because these 2 comparisons showed no difference among the celecoxib dose regimens, the analysis proceeded to combine the data with separate Cox models constructed for each trial. For each study, the natural log of the hazard ratio was estimated, along with its standard error. The 2 resulting log hazard ratios were combined by weighting each one by the inverse of its estimated variance. The SE of this combined log hazard ratio was calculated by standard methods, and the 95% CI was calculated. Finally, the hazard ratio and its confidence interval were calculated from the log hazard ratio. This process was used for each composite end point. Data are presented for the individual doses in each trial and for the pooled analysis. To assess the robustness of the estimates, a combined Cox model was constructed with terms for trial (APC or PreSAP) and celecoxib use (yes or no) to estimate the hazard ratio. A priori, we assumed that this model would produce estimates very close to those produced by the inverse variance method except for the end points of cardiovascular death and cardiovascular death plus myocardial infarction, which had Ͻ30 events in each trial.
Subgroup Analysis: Cardiovascular Risk and Aspirin Use
We used the full combined data set to determine whether patients with a history of prior cardiovascular (atherosclerotic or cerebrovascular) disease had a differential risk of adverse cardiovascular events when taking celecoxib. We constructed 2 Cox models, both stratified by study, baseline aspirin use, and history of cardiovascular disease. One model included a term for the interaction between history of cardiovascular disease and celecoxib; we used the difference between the Ϫ2log likelihoods from the model to assess the statistical significance of the interaction term. Analogous analyses were performed to examine whether the effect of celecoxib differed between those who did and did not take low-dose aspirin at baseline.
Independence From Sponsor and Statement of Responsibility
The Cardiovascular Safety Committee received baseline data for both the APC and PreSAP trials. The committee constructed a database of the cardiovascular events, designed and performed all analyses completely independently of both sponsors, and presented the results of the initial analysis first to the Data Safety Monitoring boards of each study. The results of analyses in this article were reported directly to both sponsoring organizations on completion.
The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.
Results
Baseline characteristics, including baseline medication use, for patients enrolled in APC and PreSAP were well balanced within each study (Table 1) . Between studies, patients were similar with respect to age, distribution of gender, history of diabetes, and history of prior cardiovascular disease. Compared with APC patients, PreSAP patients had a lower prevalence of hypertension, a higher rate of cigarette smoking, and a lower use of aspirin and lipid-lowering drugs.
For the cardiovascular end points, all patients in APC had at least 2.6 years of follow-up, and 77% had 37 months of follow-up. In PreSAP, 83% had at least 2 years of follow-up, and 54% had 37 months of follow-up. Individual component cardiovascular outcomes for the 2 studies are shown in Table  2 . Event rates (per 1000 patient-years) and hazard ratios, relative to placebo, for each predefined composite end point are shown for each study in Table 3 . Time to event is shown in Kaplan-Meier curves ( Figure 1 ). As reported previously for APC, 6 the data showed a significantly increased hazard for the primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure in the patients taking celecoxib 200 mg twice daily (hazard ratio, 2.6; 95% CI, 1.1 to 6.1) and 400 mg twice daily (hazard ratio, 3.4; 95% CI, 1.5 to 7.9). In PreSAP, 400 mg once daily was not associated with a statistically significant increased risk of the primary cardiovascular composite outcome (hazard ratio, 1.3; 95% CI, 0.6 to 2.6); however, comparing the 2 celecoxib arms in APC and comparing the hazard ratios in APC and PreSAP did not show statistical evidence of heterogeneity among dose regimens with respect to increased cardiovascular risk (P for heterogeneityϭ0.7 for 2 APC doses; Pϭ0.13 for APC versus PreSAP). Therefore, we performed a combined analysis of APC and PreSAP, which overall demonstrated a significantly increased risk for the composite of cardiovascular death, myocardial infarction, stroke, or heart failure (hazard ratio, 1.9; 95% CI, 1.1 to 3.1; Figure 2 ). In the combined analysis, adding other nonfatal cardiovascular outcomes, unstable angina, cardiovascular procedure, or other nonspecified cardiovascular event to this primary composite showed statistically significant hazard ratios, ranging from 1.4 to 1.7. The combined analysis did not show a differential effect of celecoxib among patients who were or were not taking low-dose aspirin, nor among patients with and without a history of prior cardiovascular disease, although the absolute risk was clearly higher in patients with history of prior cardiovascular disease (Table 4 ).
Blood Pressure Analysis
Blood pressure at baseline and 1 and 3 years and changes in blood pressure in both the APC and PreSAP studies are shown in Table 5 . The percentage of people with blood pressure measurements at years 1 and 3 were 89% and 76% in APC and 88% and 87% in PreSAP (Table 5 ). The APC trial showed a statistically significant increase in mean systolic blood pressure compared with placebo at 1 year in both the 200-mg (difference, 2.0 mm Hg; Pϭ0.04) and the 400-mg (2.9 mm Hg; Pϭ0.005) -twice-daily dose groups and in both dose groups at 3 years (200 mg, 2.6 mm Hg; Pϭ0.03; 400 mg, 5.2 mm Hg; PϽ0.001; difference between doses, Pϭ0.02). There was no difference in blood pressure between placebo and celecoxib 400 mg once daily in PreSAP at either 1 or 3 years. The differences between the changes between PreSAP and APC were highly significant (PϽ0.0001 for both 1 and 3 years). Similarly, the data showed dose-related increases in the percentage of patients with systolic blood pressure changes Ն10 and 15 mm Hg in APC that are significant at 3 years (PϽ0.001) but not in PreSAP (Table 5) .
Discussion
Both the APC and PreSAP trials were designed with high statistical power to assess the efficacy of celecoxib in reducing the recurrence of colorectal adenomas. Although our HR indicates hazard ratio. *Any cardiovascular event includes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, unstable angina, cardiovascular procedure, or any other event deemed cardiovascular in nature.
analysis of cardiovascular events was blinded and based on adjudicated prespecified outcomes, this safety analysis is based on few events and thus has limited statistical power. Although an increased cardiovascular risk was associated with both doses in APC, the similarly conducted PreSAP trial did not demonstrate a significant increase in cardiovascular risk associated with celecoxib 400 mg once daily; however, because of the small number of events and wide CIs, the data do not exclude a hazard ratio of the magnitude observed in APC.
Despite the low number of cardiovascular events, these trials in combination represent the most extensive long-term placebo-controlled experience with celecoxib, with a total of 10 500 patient-years of cumulative follow-up for cardiovascular events. This combined analysis, which showed a nearly 2-fold increased risk of cardiovascular death, myocardial infarction, stroke, or heart failure associated with celecoxib 400 mg daily or higher (Figure 2 ), uses individual patient data. This method has advantages over more traditional meta-analytic approaches by maintaining the randomization structure of each study and using time-to-event data and the baseline strata to provide a more precise estimate of the hazard ratio. Moreover, we can assess more thoroughly whether celecoxib has a differential effect for patients with various baseline characteristics. Finally, access to the raw data allows presentation of the timing of individual events. Although the test for heterogeneity between trials was not statistically significant, suggesting that the pooling of these data is valid, a graded response in the 3 dose groups forces some caution in the interpretation of these results and reinforces the statistical uncertainty inherent in an analysis with few events.
The assessment of blood pressures provides another approach to evaluate whether the cardiovascular effect of celecoxib 400 mg once daily differs from 200 or 400 mg twice daily. 10 The blood pressure data, which are less encumbered by low statistical power, may provide biologically relevant support for the findings on outcomes. Some prior observational and short-term placebo-controlled data have suggested that celecoxib has less effect on blood pressure than do other agents in this class. 11, 12 Schwartz et al 13 reported that 14 days of treatment with celecoxib 200 mg twice daily increased systolic blood pressure (4.3 mm Hg) by an amount similar to rofecoxib 25 mg once daily (3.4 mm Hg) and naproxen 500 mg twice daily (3.1 mm Hg) compared with placebo (Ϫ1.3 mm Hg). Conversely, a much larger study recently found that neither celecoxib 200 mg once daily nor naproxen 500 mg twice daily increased blood pressure, whereas rofecoxib 25 mg once daily did. 14 We observed a graded response on systolic blood pressure in the 2 trials, with no change on average with 400 mg QD and a dose-related increase with 200 to 400 mg BID. Although in a prior study, no increase in blood pressure was observed at the time of expected trough plasma levels during once daily dosing, an increase in blood pressure of a magnitude similar to that seen in APC has been seen at peak dosing. 15 Thus, the timing of blood pressure measurements related to the dosing of celecoxib may be important for the interpretation of these results, and it is conceivable that once-daily dosing simply results in a less sustained blood pressure effect than twice-daily dosing. This hypothesis is supported by ambulatory blood pressure data suggesting that there was a 2-to 4 -mm Hg increase in systolic blood pressure over the 4 hours after dosing of celecoxib. 16 Alternatively, the relatively short half-life of celecoxib is a potential explanation for the apparent differential blood pressure response between the 2 trials; however, this hypothesis has not been rigorously tested. 17, 18 The suggestion of BP indicates blood pressure. *Means are compared with study-specific placebo means. The difference between the changes in systolic blood pressure at 3 years in the 200 and 400 mg BID groups in APC is statistically significant (Pϭ0.02). The difference between the changes in systolic blood pressure between PreSAP and APC are highly significant (PϽ0.0001 for both 1 and 3 years). The analyses are based on ANOVA for systolic and diastolic blood pressure with study, dose, and aspirin use at baseline as the independent variables. †Because of pronounced digit preference, the observations were smoothed using a 3-point rectangular smoother to obtain more accurate estimates of means and of percentages Ͼ10 and 15 mm Hg. To assess the robustness of the results, we tested the raw data and other smoothing strategies; all produced similar effect sizes. At 1 year, all probability values are Ͼ0.01 for differences at 1 year between any 2 doses within trials and the differences between changes from placebo to any dose between APC and PreSAP. At 3 years, the probability comparing differences between the 400 mg BID and placebo doses in APC are Ͻ0.001 for both 10 short-lived inhibition of endothelial COX-2 and subsequent recovery of that enzyme during once-daily dosing 17 needs to be tested prospectively. Nevertheless, the low number of overall events in these studies, the fact that these studies of polyp prevention did not define a protocol for measuring blood pressure, and the fact that earlier blood pressure measurements were not recorded limit our ability to determine whether blood pressure elevations underlie the cardiovascular risks observed.
In these studies, all 3 doses of celecoxib examined were effective in reducing the number of adenomatous polyps and higher-grade histological lesions. 7, 8 Whether lower doses would be effective for this purpose is unknown, although a trend for a reduction in polyps in a smaller study of patients with familial adenomatous polyposis has been observed with a dose of 100 mg twice daily. 19 Most patients exposed to celecoxib take the drug for pain relief. The usual dose of celecoxib for arthritis pain relief (average daily dose, 200 mg) is lower than the doses tested in APC and PreSAP. The cardiovascular risk associated with usual analgesic doses is unknown and cannot be reliably estimated from the available small, short-term, placebo-controlled trials or the many observational studies with their inherent limitations. Moreover, we cannot reliably extrapolate our data to short-term use of celecoxib because these studies do not have sufficient power to allow assessment of the true time course of the cardiovascular risk. Nevertheless, physicians must recognize the increased potential for cardiovascular risk compared with placebo when considering celecoxib for pain relief.
We undertook this comprehensive analysis of cardiovascular safety only after substantial public concern had been raised about the safety of rofecoxib. Moreover, neither APC nor PreSAP was designed or powered to assess cardiovascular risk. Thus, the results of this analysis are limited by the statistical uncertainty arising from the small total number of events. Indeed, a potential explanation for the smaller relative risk associated with celecoxib in PreSAP compared with APC is the higher placebo event rate in that trial (7.2 of 100 patient-years in PreSAP compared with 3.4 of 1000 patientyears in APC), although these rates are based on only 7 and 12 placebo events, respectively. Thus, chance is a possible explanation for the apparently discrepant hazard related to celecoxib in the 2 trials. Finally, the data in this article differ minimally from the data originally presented to the 2 Data Safety Monitoring boards and from original report describing the cardiovascular end points in APC 6 because, during the year from stopping the study to closing the database, some baseline data were updated, and a few additional cardiovascular events were identified.
Conclusions
In summary, we observed a nearly 2-fold increased risk of the composite end point of cardiovascular death, myocardial infarction, stroke, or heart failure when combining all doses of celecoxib tested in 2 similar placebo-controlled, long-term cancer prevention trials. The observed dose-related increase in cardiovascular events and blood pressure raises the possibility that even lower once-daily dose regimens may be associated with lower overall cardiovascular hazard. Further research is needed to determine whether lower doses of celecoxib would provide pain relief and adenomatous polyp prevention with a clinically acceptable level of cardiovascular risk.
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